Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
AGIO

AGIO - Agios Pharmaceuticals Inc Stock Price, Fair Value and News

44.05USD-2.72 (-5.82%)Market Closed

Market Summary

AGIO
USD44.05-2.72
Market Closed
-5.82%

AGIO Alerts

  • 1 major insider sales recently.
  • Losses in recent quarter

AGIO Stock Price

View Fullscreen

AGIO RSI Chart

AGIO Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-7.53

Price/Sales (Trailing)

88

EV/EBITDA

-7.2

Price/Free Cashflow

-8.81

AGIO Price/Sales (Trailing)

AGIO Profitability

EBT Margin

-1166.86%

Return on Equity

-47.4%

Return on Assets

-41.5%

Free Cashflow Yield

-11.35%

AGIO Fundamentals

AGIO Revenue

Revenue (TTM)

30.2M

Rev. Growth (Yr)

-18.85%

Rev. Growth (Qtr)

-31.19%

AGIO Earnings

Earnings (TTM)

-352.6M

Earnings Growth (Yr)

-0.66%

Earnings Growth (Qtr)

15%

Breaking Down AGIO Revenue

Last 7 days

-2.2%

Last 30 days

36.9%

Last 90 days

56.2%

Trailing 12 Months

81.7%

How does AGIO drawdown profile look like?

AGIO Financial Health

Current Ratio

12.84

AGIO Investor Care

Shares Dilution (1Y)

2.14%

Diluted EPS (TTM)

-6.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202430.2M000
202317.2M23.7M27.5M27.6M
202285.0M45.6M6.3M12.3M
20210163.8M124.4M0
2020174.8M184.3M193.7M203.2M
2019115.9M101.7M112.5M117.9M
201841.3M70.3M74.2M94.4M
201749.1M53.5M55.9M43.0M
201670.7M64.5M68.0M69.9M
201562.0M66.9M38.4M44.6M
201427.7M29.8M57.5M65.4M
201325.1M25.1M25.1M25.5M
201222.7M23.5M24.3M25.1M
201100021.8M

Tracking the Latest Insider Buys and Sells of Agios Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 05, 2024
goff brian
sold
-591,697
48.84
-12,115
chief executive officer
Jun 05, 2024
goff brian
acquired
-
-
25,527
chief executive officer
Jun 03, 2024
washburn theodore james jr.
sold
-60,459
44.39
-1,362
principal accounting officer
Apr 10, 2024
fouse jacqualyn a
sold
-214,642
27.55
-7,791
-
Apr 08, 2024
fouse jacqualyn a
acquired
-
-
15,934
-
Mar 07, 2024
foster-cheek kaye i
sold
-40,631
31.62
-1,285
-
Mar 06, 2024
foster-cheek kaye i
sold
-141,236
31.99
-4,415
-
Mar 05, 2024
jones cecilia
sold
-21,887
32.57
-672
chief financial officer
Mar 05, 2024
gheuens sarah
sold
-86,049
32.57
-2,642
chief medical officer
Mar 05, 2024
burns james william
sold
-86,049
32.57
-2,642
chief legal officer

1–10 of 50

Which funds bought or sold AGIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-64.41
-631
683
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
248,000
1,149,000
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
34.14
70,656,700
163,469,000
0.74%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.64
171,207
315,207
0.04%
May 17, 2024
Aspect Partners, LLC
unchanged
-
2,517
10,556
0.01%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.01
323,554
1,632,670
-%
May 16, 2024
JANE STREET GROUP, LLC
added
27.05
1,458,480
3,641,400
-%
May 16, 2024
COMERICA BANK
added
234
5,042
6,534
-%
May 16, 2024
Tidal Investments LLC
new
-
945,505
945,505
0.02%
May 15, 2024
Voya Investment Management LLC
reduced
-28.96
-206,925
2,869,960
-%

1–10 of 42

Are Funds Buying or Selling AGIO?

Are funds buying AGIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGIO
No. of Funds

Unveiling Agios Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
6.31%
3,524,000
SC 13G/A
Feb 14, 2024
rock springs capital management lp
3.85%
2,152,173
SC 13G/A
Feb 13, 2024
bb biotech ag
7.2%
4e+06
SC 13G/A
Feb 12, 2024
vanguard group inc
10.02%
5,599,917
SC 13G/A
Feb 12, 2024
vanguard group inc
9.89%
5,527,438
SC 13G/A
Feb 08, 2024
farallon capital partners, l.p.
0.6%
350,343
SC 13G/A
Jan 25, 2024
blackrock inc.
8.9%
4,962,237
SC 13G/A
Jan 22, 2024
state street corp
4.70%
2,625,685
SC 13G/A
Nov 09, 2023
farallon capital partners, l.p.
0.6%
332,366
SC 13G
Nov 09, 2023
wellington management group llp
3.95%
2,200,757
SC 13G/A

Recent SEC filings of Agios Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 07, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
144
Notice of Insider Sale Intent
May 28, 2024
8-K
Current Report
May 02, 2024
8-K
Current Report
May 02, 2024
10-Q
Quarterly Report
Apr 26, 2024
DEFA14A
DEFA14A
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
ARS
ARS
Apr 10, 2024
4
Insider Trading

Peers (Alternatives to Agios Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Agios Pharmaceuticals Inc News

Latest updates
MarketBeat3 hours ago

Agios Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q32021Q22020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue29.3%8,189,0006,332,0007,399,0008,254,0005,609,0006,273,5003,516,0001,793,000694,000256,00022,150,50044,045,0001,115,00044,106,50087,098,00035,440,00026,024,00026,221,00030,227,00030,013,00015,198,000
Costs and Expenses-11.6%100,261,000113,380,000108,296,000100,412,00096,222,000103,482,00094,606,000103,222,000101,977,00091,152,00091,222,00085,332,00080,290,00083,264,00087,030,000-86,607,000135,084,000140,082,000127,710,000--
Operating Expenses-----------------135,084,000140,082,000127,710,000126,369,000114,360,000
  S&GA Expenses-12.2%31,014,00035,305,00025,822,00030,409,00028,367,00032,771,00029,123,00028,264,00031,515,00027,152,00029,215,00025,908,50028,347,00029,178,00031,672,0004,807,00033,019,00032,390,00031,791,00031,858,00031,104,000
  R&D Expenses-11.4%68,620,00077,489,00081,841,00068,895,00067,301,00070,298,00064,966,00074,523,00070,123,00064,000,00062,007,00059,423,50051,943,00054,086,00055,358,000-90,384,000101,672,000107,389,00095,585,00093,809,00082,561,000
EBITDA Margin8.6%-11.67-12.76-7.42-8.53-11.33-18.15-55.53-7.61-4.09-2.68-2.00----------
Income Taxes-2988.2%-525,000-17,000785,000801,000--1,940,00098,000-1,842,0002,716,0006,200,000----------
Earnings Before Taxes------33,832,000----84,259,000-82,790,000-84,541,000-79,175,000-81,495,000-84,094,000------
EBT Margin8.6%-11.67-12.76-7.72-8.87-11.78-18.88-56.96-7.81-4.19-2.75-2.06----------
Net Income15.0%-81,549,000-95,940,000-91,324,000-83,806,000-81,018,00036,526,000-81,747,000-91,806,000-94,774,000-88,766,000-86,217,000-97,657,000-98,979,000-90,478,000-40,256,000-102,350,000-106,173,000-109,871,000-93,078,000-91,794,000-94,664,000
Net Income Margin8.4%-11.69-12.76-7.32-8.04-11.08-18.88-57.99-8.11-4.2912.879.72----------
Free Cashflow-37.5%-100,008,000-72,722,000-62,012,000-66,745,000-95,582,000-66,276,000-71,389,000-76,155,000-100,539,000-85,162,000-117,543,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-9.3%8509371,0071,0851,1511,2391,1801,2521,3361,4381,5411,8752,488853908976800891699784822
  Current Assets-20.4%6648347047577928337858709751,0641,3051,7032,355637669846587612490534557
    Cash Equivalents34.6%11988.0064.0085.0010413912289.0080.002034009691,88812710529689.0081.0082.0084.00103
  Inventory20.9%23.0019.0017.0016.0011.008.005.004.002.00----15.0011.0011.0010.007.006.005.002.00
  Net PPE-8.2%14.0015.0017.0020.0021.0023.0025.0027.0029.0029.0025.0027.0029.0031.0033.0034.0034.0031.0024.0023.0024.00
Liabilities-16.1%106126120121115138130128128146147153192453428418174250250251202
  Current Liabilities-23.9%52.0068.0058.0055.0045.0063.0054.0048.0046.0060.0058.0061.0097.0094.0070.0064.0070.0093.0092.0090.0081.00
Shareholder's Equity-8.3%7448118879641,0371,1011,0501,1241,2071,2921,3951,7222,297400480558625641448533620
  Retained Earnings-9.9%-904-822-726-635-551-470-507-425-333-238-144-55.3731.00-1,843-1,745-1,646-1,556-1,516-1,413-1,307-1,197
  Additional Paid-In Capital0.6%2,4522,4372,4222,4112,3992,3862,3752,3622,3512,3342,3222,3062,2662,2432,2262,2042,1822,1561,8621,8401,818
Shares Outstanding1.4%57.0056.0056.0056.0055.0055.0055.0055.0055.0060.0063.0065.00---------
Float----1,558---1,200---3,268---3,280---2,563-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-37.8%-99,867-72,488-61,643-66,748-95,183-66,163-71,351-74,229-97,735-84,093-85,184-117,294-120,749-49,397-68,207-67,797-105,358-93,611-85,589-88,151-103,271
  Share Based Compensation-33.2%9,23413,8149,07611,73710,13911,46511,15611,16515,51011,62112,14814,88514,85413,34114,97717,61415,6702,80718,58818,54718,108
Cashflow From Investing30.4%124,56295,51339,34147,12557,59682,951104,07082,813-26,573-94,419-232,731-298,1491,874,07771,396-126,24422,459108,135-184,77380,38164,480131,352
Cashflow From Financing592.3%5,8648471,8822372,46722.001,187-67.001,208-18,586-250,985-503,4587,2615823,448252,1035,385277,6063,3373,8084,860
  Buy Backs----------19,048254,391----------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AGIO Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenue$ 8,189$ 5,609
Operating expenses:  
Cost of sales627554
Research and development68,62067,301
Selling, general and administrative31,01428,367
Total operating expenses100,26196,222
Loss from operations(92,072)(90,613)
Interest income, net8,8898,091
Other income, net1,6341,504
Net loss$ (81,549)$ (81,018)
Net loss per share - basic (in usd per share)$ (1.45)$ (1.47)
Net loss per share - diluted (in usd per share)$ (1.45)$ (1.47)
Weighted-average number of common shares used in computing net loss per share - basic (in shares)56,383,47555,265,390
Weighted-average number of common shares used in computing net loss per share – diluted (in shares)56,383,47555,265,390
Product revenue, net  
Revenues:  
Total revenue$ 8,189$ 5,609

AGIO Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 118,764$ 88,205
Marketable securities479,227688,723
Accounts receivable, net3,4532,810
Inventory23,07019,076
Prepaid expenses and other current assets39,11335,021
Total current assets663,627833,835
Marketable securities116,30129,435
Operating lease assets51,60654,409
Property and equipment, net14,11915,382
Other non-current assets4,0564,057
Total assets849,709937,118
Current liabilities:  
Accounts payable11,1559,780
Accrued expenses25,12943,167
Operating lease liabilities15,40715,008
Total current liabilities51,69167,955
Operating lease liabilities, net of current portion52,94056,988
Other non-current liabilities1,1561,156
Total liabilities105,787126,099
Stockholders’ equity:  
Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.001 par value; 125,000,000 shares authorized; 72,967,922 shares issued and 56,751,511 shares outstanding at March 31, 2024, and 72,161,489 shares issued and 55,945,078 shares outstanding at December 31, 20237372
Additional paid-in capital2,451,6202,436,523
Accumulated other comprehensive loss(1,087)(441)
Treasury stock, at cost (16,216,411 shares at March 31, 2024 and December 31, 2023)(802,486)(802,486)
Accumulated deficit(904,198)(822,649)
Total stockholders’ equity743,922811,019
Total liabilities and stockholders’ equity$ 849,709$ 937,118
AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEagios.com
 INDUSTRYBiotechnology
 EMPLOYEES389

Agios Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Agios Pharmaceuticals Inc? What does AGIO stand for in stocks?

AGIO is the stock ticker symbol of Agios Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agios Pharmaceuticals Inc (AGIO)?

As of Thu Jun 13 2024, market cap of Agios Pharmaceuticals Inc is 2.66 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers. The fair value of Agios Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agios Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agios Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AGIO is over valued or under valued. Whether Agios Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Agios Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGIO.

What is Agios Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, AGIO's PE ratio (Price to Earnings) is -7.53 and Price to Sales (PS) ratio is 88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agios Pharmaceuticals Inc's stock?

In the past 10 years, Agios Pharmaceuticals Inc has provided -0.001 (multiply by 100 for percentage) rate of return.